1
|
França K, Hercogovấ J, Fioranelli M, Gianfaldoni S, Chokoeva AA, Tchernev G, Wollina U, Tirant M, Bayer P, Coburn M, Anderson P, Donnelly B, Kennedy T, Gaibor J, Arora M, Clews L, Novotny F, Roccia MG, Maximov GK, Lotti T. Investigation of the efficacy and tolerability of Dr Michaels® (also branded as Eczitinex® and Itchinex Eczitinex®) topical products in the treatment of atopic dermatitis in children. J BIOL REG HOMEOS AG 2016; 30:55-63. [PMID: 27498659] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Atopic eczema is a chronic relapsing inflammatory skin disorder, characterized clinically by intensely pruritic eczematous skin lesions and a defective epidermal barrier. It affects more than 15% of children and up to 10%of adults, which makes the disease a social health problem still without a challenging treatment. The aim of this study was to evaluate the efficacy and tolerability of Dr Michaels® (Eczitinex®) topical product family in the treatment of atopic dermatitis in children. We studied a group of 30 patients (17 female, 13 male), aged 5 to 13 (mean age: 9), affected by atopic dermatitis since they were newborn. All patients had been unsuccessfully treated with conventional anti-inflammatory therapies and ceased treatment 2 weeks before commencing research. The patients were treated with Dr Michaels® (Eczitinex® and Itchinex®) product family including a moisturising bar, topical ointment and PSC 900 oral herbal formulation. The treatment was evaluated clinically and photographically at 0, 1, 2, 4, 6, 8, 10, 12, and 14 weeks. Twenty-eight patients showed a significant improvement of cutaneous rashes and pruritus on the first week of treatment, with a complete remission at 10-12 weeks. Only two patients, brother and sister respectively, showed a slow response to treatment and reported an increasing itching. Following 14 weeks of treatment with the Dr Michaels® (Eczitinex® and Itchinex®) product family, patients demonstrated complete resolution of their AD. All patients showed a marked improvement in their condition within 3 days of treatment with most of the lesions and symptoms totally resolved within 10 to 12 weeks of treatment with Dr Michaels® (Eczitinex® and Itchinex®) family of products. This clinical report highlights that the Dr Michaels® (Eczitinex® and Itchinex®) product family is a safe and effective treatment option for AD.
Collapse
Affiliation(s)
- K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy
| | - J Hercogovấ
- 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
| | - M Fioranelli
- Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy
| | - S Gianfaldoni
- Dermatological Department University of Pisa, Pisa, Italy
| | - A A Chokoeva
- Onkoderma-Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; 7 Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - M Tirant
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - P Bayer
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - M Coburn
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - P Anderson
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - B Donnelly
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - T Kennedy
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - J Gaibor
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - M Arora
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - L Clews
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - F Novotny
- PRO SANUM Ltd, Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G K Maximov
- Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria
| | - T Lotti
- Chair of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
2
|
Wollina U, Tirant M, Bayer P, Coburn M, Anderson P, Donnelly B, Kennedy T, Gaibor J, Arora M, Clews L, Walmsley S, Hercogovấ J, Fioranelli M, Gianfaldoni S, Chokoeva AA, Tchernev G, Novotny F, Roccia MG, Maximov GK, França K, Lotti T. Successful treatment of mild to moderate acne vulgaris with Dr Michaels® (also branded as Zitinex®) topical products family: a clinical trial. J BIOL REG HOMEOS AG 2016; 30:49-54. [PMID: 27498658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Acne vulgaris is an epidemic inflammatory skin disease of multi-factorial origin, frequently seen in adolescents and often persisting or occurring through to adulthood. Acne vulgaris is a nearly universal skin disease afflicting 79-95% of the adolescent population in westernized societies and is a significant cause of psychological morbidity in affected patients. Despite the various treatment options available for acne, there is still a need for a safe and effective option. The aim of the study was to investigate the efficacy and tolerability of Dr Michaels® (Zitinex®) product family in the treatment of papulo-pustular acne. 25 patients (17 female/8 male), aged 15-22, with a mild to moderate papulo-pustular acne, localized on the face and on the trunk, were included in this study. None of the patients had used any other kind of treatment in the 3 months prior to commencing this study. All of the patients were treated with Dr Michaels® (Zitinex®) facial exfoliating cleanser, activator formula, a cream, PSC 200 and PSC 900 oral supplements. Application time of Dr Michaels® (Zitinex®) products was 12 weeks. The treatment was been evaluated clinically at 0, 4, 8 and 12 weeks. All of the patients showed an improvement in all parameters of their acne (comedones, papules, pustules, hyperpigmentation and scars). The acne lesions and erythema had mostly resolved. The hyperpigmentation and pitted scarring had significantly reduced also, with the skin appearing smoother. The treatment was well tolerated and no side effects have been described. Our study demonstrates that the Dr Michaels® (Zitinex®) facial exfoliating cleanser, activator formula, cream and oral supplements PSC 200 and PSC 900 are an effective therapeutic option for the treatment of moderately severe acne vulgaris. Moreover, it highlights the safety profile of the Dr Michaels® (Zitinex®) product family in a case of acne compared to traditional first-line treatments.
Collapse
Affiliation(s)
- U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - M Tirant
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - P Bayer
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - M Coburn
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - P Anderson
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - B Donnelly
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - T Kennedy
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - J Gaibor
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - M Arora
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - L Clews
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - S Walmsley
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - J Hercogovấ
- 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
| | - M Fioranelli
- Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy
| | - S Gianfaldoni
- Dermatological Department University of Pisa, Pisa, Italy
| | - A A Chokoeva
- Onkoderma- Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - F Novotny
- PRO SANUM Ltd., Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G K Maximov
- Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria
| | - K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy
| | - T Lotti
- Chair of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
3
|
Hercogovấ J, Tirant M, Bayer P, Coburn M, Donnelly B, Kennedy T, Gaibor J, Arora M, Clews L, Fioranelli M, Gianfaldoni S, Chokoeva AA, Tchernev G, Wollina U, Novotny F, Roccia MG, Maximov GK, França K, Lotti T. Successful treatment of recalcitrant candidal intertrigo with Dr Michaels® (Fungatinex®) product family. J BIOL REG HOMEOS AG 2016; 30:89-93. [PMID: 27498664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Candidal intertrigo is an infection of the skin caused by Candida albicans that typically occurs in opposing cutaneous or muco-cutaneous surfaces. Because Candidiasis requires a damaged and moist environment for infection, it typically occurs in areas of friction such as the skin folds of the body. Candidal intertrigo is often difficult to treat and results are often unsatisfactory. In addition, there is a lack of evidence-based literature supporting prevention and treatments for candidal intertrigo. The aim of the study was to evaluate the efficacy of Dr Michaels® (also branded as Fungatinex®) products in the treatment of fungal intertrigo, in 20 women and 2 men with a mean age of 72. Five patients (3 female and 2 male) had type 2 diabetes and 16 (14 female and 2 male) were obese. The patients were treated with Dr Michaels® (Fungatinex®) moisturising bar, topical ointment (twice daily application) and oral herbal formulation, PSC 200 two tablets twice daily with food. After 2 weeks of treatment, the lesions had mostly resolved in all patients with only slight erythema evident. After six weeks of treatment using the moisturising bar, topical ointment and oral herbal formulations from the Dr Michaels® (Fungatinex®) product family, the lesions had totally resolved in 18 patients, while 4 patients had to continue the therapeutic protocol for another 2 weeks. Our results demonstrate that the Dr Michaels® (Fungatinex®) complementary product family is efficacious in the treatment of recalcitrant candidal intertrigo. Furthermore, this study highlights that the Dr Michaels® (Fungatinex®) product family is fast-acting and well tolerated with no serious adverse events reported. These data have important implications for resistant cases of candidal intertrigo where traditional therapies have failed.
Collapse
Affiliation(s)
- J Hercogovấ
- 2nd Medical Faculty, Charles University, Bulovka Hospital, Institute of Clinical and Experimental Medicine, Prague, Czech Republic
| | - M Tirant
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - P Bayer
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - M Coburn
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - B Donnelly
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - T Kennedy
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - J Gaibor
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - M Arora
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - L Clews
- Psoriasis and Skin Clinic, Melbourne, Australia
| | - M Fioranelli
- Department of Nuclear Physics, Sub-nuclear and Radiation, Guglielmo Marconi University, Rome, Italy
| | - S Gianfaldoni
- Dermatological Department University of Pisa, Pisa, Italy
| | - A A Chokoeva
- Onkoderma-Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria
| | - G Tchernev
- Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria
| | - U Wollina
- Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
| | - F Novotny
- PRO SANUM Ltd, Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic
| | - M G Roccia
- University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India
| | - G K Maximov
- Department Medicinal Information and Non-interventional studies, Bulgarian Drug Agency, Sofia, Bulgaria
| | - K França
- Department of Dermatology and Cutaneous Surgery, Department of Psychiatry and Behavioral Sciences, Institute for Bioethics and Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy
| | - T Lotti
- Chair of Dermatology, University of Rome G. Marconi Rome, Italy
| |
Collapse
|
4
|
Manning PJ, Gaibor J, Delong D, Gunther R. Enzyme-linked immunosorbent assay and immunoblot analysis of the immunoglobulin G response to whole-cell and lipooligosaccharide antigens of Pasteurella pneumotropica in laboratory mice with latent pasteurellosis. J Clin Microbiol 1989; 27:2190-4. [PMID: 2584371 PMCID: PMC266991 DOI: 10.1128/jcm.27.10.2190-2194.1989] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
The immunoglobulin G (IgG) response to whole-cell and lipooligosaccharide (LOS) antigens of Pasteurella pneumotropica was evaluated in mice with latent pasteurellosis by enzyme-linked immunosorbent assay (ELISA) and immunoblots. Antibodies to cell wall proteins of P. pneumotropica also reacted with several protein antigens from isolates of Actinobacillus spp. and other pasteurellae. Conversely, antibodies to LOS antigens of P. pneumotropica demonstrated no cross-reactivity with LOSs of other Pasteurella or Actinobacillus species. IgG to cell wall proteins was detected initially by ELISA 4 weeks after experimental oronasal inoculation of specific-pathogen-free mice; antibody to LOSs was first detected 7 weeks after infection and at that time exceeded titers to other cell wall antigens. Naturally infected conventional mice from a colony with endemic latent pasteurellosis had high IgG titers to P. pneumotropica antigens at 8 to 10 weeks of age, and, as in the experimentally infected mice, antibody to LOSs predominated. Thus, LOSs of P. pneumotropica can be used as an ELISA or immunoblot antigen to detect serospecific antibodies in laboratory mice with latent pasteurellosis.
Collapse
Affiliation(s)
- P J Manning
- Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis 55455
| | | | | | | |
Collapse
|